We are pleased to announce that John Kauh, M.D., Chief Medical Officer of Tvardi Therapeutics, will present preclinical data on TTI-101 that supports the mechanistic rationale for our Phase 2 REVERT IPF Clinical Trial at the CHEST 2024 Annual Meeting on October 8th, 2024, in Boston, MA. https://lnkd.in/g9t7FDvz
Tvardi Therapeutics
生物技术研究
Houston，TX 2,072 位关注者
Breakthrough Medicines for Cancer, Chronic Inflammation & Fibrosis
关于我们
Tvardi is a privately held, clinical-stage, biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting Phase 2 clinical trials in fibrosis-driven diseases with high unmet need: idiopathic pulmonary fibrosis (NCT05671835) and hepatocellular carcinoma (NCT05440708).
- 网站
-
https://www.tvardi.com
Tvardi Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Houston，TX
- 类型
- 私人持股
- 创立
- 2017
- 领域
- STAT3、Small Molecules、Cancer、Inflammation和Fibrosis
地点
-
主要
获取路线
2450 Holcombe Blvd, Suite X
US，TX，Houston，77021
Tvardi Therapeutics员工
动态
-
Tvardi is proud to be an official sponsor for the Pulmonary Fibrosis Foundation PFF Walk 2024 taking place this Saturday, September 14th in Chicago. Please join Tvardi’s leadership team and other members of the PFF community as we walk together toward a cure in the Windy City! We look forward to seeing everyone there! ? If you have not registered yet for the PFF Walk, please register here: https://lnkd.in/d9YTZQ5Z
-
-
We are pleased to announce that Imran Alibhai, PhD, Chief Executive Officer of Tvardi Therapeutics, was selected to make a presentation and co-lead a panel discussion at the 8th Annual IPF Summit being held in Boston, MA on August 22, 2024. #IdiopathicPulmonaryFibrosis #ClinicalTrial https://lnkd.in/gTi9iGSN
-
-
Tvardi Therapeutics will participate in a #firesidechat at 10:00 AM ET on August 6th and will hold one-on-one investor meetings on August 5-6 at the 2024 BTIG Virtual Biotechnology Conference. #HepatocellularCarcinoma #LiverCancer #IdiopathicPulmonaryFibrosis #ClinicalTrial https://lnkd.in/gmNbPE3g
-
-
We are pleased to announce the appointment of Sujal Shah as Chairman and the addition of Shaheen Wirk to the Tvardi Board of Directors. https://lnkd.in/gM5HWuVp
-
-
Tvardi management will hold one-on-one investor meetings at the Cowen Inc. 44th Annual Health Care Conference on March 4, 2024, in Boston, MA https://lnkd.in/gE6dtamd
-
-
We are excited to share that Tvardi leadership will present a trial-in-progress poster at the upcoming 2024 ASCO Gastrointestinal Cancers Symposium for the ongoing REVERT LIVER CANCER trial https://lnkd.in/gfE78zTs
-